What happened
Fate Therapeutics, Inc. (NASDAQ: FATE) said the California Institute for Regenerative Medicine awarded it a $15.0 million CLIN2 grant on September 25, 2026. The grant supports RECLAIM-LN, a Phase 2, potentially registrational trial of FT819 in refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis.
RECLAIM-LN, also called FT819-201, is a multicenter, open-label, single-arm study. It is expected to enroll approximately 53 patients who are refractory to at least two prior systemic immunosuppressive therapies. The primary endpoint is the share of participants who achieve complete renal response at Week 26. Fate said the study is meant to test FT819 in a group with limited treatment options.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| CIRM grant award | $15.0 million | SEC 8-K | |
| Expected enrollment | approximately 53 patients | Press release | |
| U.S. patients with lupus nephritis | approximately 150,000 patients in the United States | Press release |
Why it matters
The award adds outside funding to the program, and the amount is about 5.3% of FATE THERAPEUTICS INC's market value. It is still a grant announcement, not a renal response result, so it supports the program without showing that FT819 works.
The release also says CLIN2 is meant to advance clinical-stage stem cell and gene therapy programs that may improve access. That fits FT819's position as an off-the-shelf therapy that can be given as outpatient treatment in the community setting. For investors, the funding helps. It does not answer the main efficacy or safety question.
Fate also said preliminary Phase 1 data showed favorable safety and tolerability and clinically meaningful improvement. Those results included sustained gains in clinical SLEDAI-2K and urine protein-to-creatinine ratio, with further reductions using less-intensive bendamustine conditioning. That is why the Week 26 readout still matters.
The RECLAIM-LN study was developed through interactions with the FDA under FT819 RMAT designation, and FT819 was also selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program. Those designations keep the program tied to later development milestones as the trial advances.
The filing mostly changes the funding backdrop. It does not change the main clinical question.
What's next
The next scheduled test is the Week 26 primary endpoint on complete renal response. A stronger readout would support the trial's potentially registrational framing.
If the endpoint lands well, the study stays on a potentially registrational path. If it misses, the CIRM award will look like funding, not validation. Investors still need the data.
Sources
- SEC 8-K — Current report reporting the CIRM grant and incorporating the press release.
- Press release — Exhibit 99.1 announcing the CLIN2 grant and RECLAIM-LN.
Read the full OptimistFi thesis on Fate Therapeutics, Inc.: https://optimistfi.com/stocks/FATE
See what would break the Fate Therapeutics, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Fate Therapeutics, Inc. investment case, its status and the next test to watch live on the Fate Therapeutics, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
